- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06149039
Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With Pulmonary Interstitial Disease
November 19, 2023 updated by: Yanfeng Hou
To detect the changes of lymphocyte subsets in peripheral blood of non-myopathic dermatomyositis with pulmonary interstitial disease, classical dermatomyositis with pulmonary interstitial disease, rheumatism with non-inflammatory myopathy with pulmonary interstitial disease and healthy adults among the 4 groups, and to detect the related cytokines secreted by lymphocyte subsets Th1,Th2 and Th17.
Clinical features, distribution of peripheral lymphocyte subsets ratio and related cytokine content secreted by each lymphocyte subset were analyzed in each group, so as to explore the pathogenesis characteristics of nonmyopathic dermatomyositis complicated with pulmonary interstitial disease, in order to facilitate clinical guidance for diagnosis and treatment.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
120
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hou Y feng
- Phone Number: 15168888165
- Email: yfhou1016@163.com
Study Locations
-
-
Shandong
-
Jinan, Shandong, China, 250000
- Recruiting
- Yanfeng Hou
-
Contact:
- Yanfeng Hou, Dr.
- Phone Number: 15168888165
- Email: yfhou1016@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Patients and healthy adults who meet inclusion criteria
Description
Inclusion Criteria:
- The experimental group met the diagnostic criteria of Sontheimer and was diagnosed as CADM with pulmonary interstitial disease.
- Control group 1: The diagnosis was consistent with the diagnostic criteria of Bohan and Perter classification system, and it was confirmed that dermatomyositis was combined with pulmonary interstitial disease;
- Control group 2: The diagnosis meets the classification criteria of systemic lupus erythematosus revised by the American College of Rheumatology (ACR) in 1997 and is confirmed as systemic lupus erythematosus combined with pulmonary interstitial disease, or the diagnosis meets the diagnostic criteria of rheumatoid arthritis introduced by ACR in 1987 or ACR in 2010 and is confirmed as rheumatoid arthritis combined with pulmonary interstitial disease.
- Age 18-70 years old;
- Have a good understanding of their own illness and physical condition, have self-knowledge, can communicate well with others;
- Voluntarily join the study, understand the significance of the experiment and the indicators to be measured, and sign the informed consent.
Exclusion Criteria:
- Severe infection: fever, cough, phlegm, sore throat, abdominal pain, diarrhea, carbuncle and other skin and soft tissue infection and other clinical manifestations, blood routine white blood cell count beyond the normal range (10×109/L);
- Severe cardiovascular disease: including chronic heart dysfunction grade 3 or above and various arrhythmias;
- Infectious diseases: hepatitis active stage, AIDS, syphilis, etc.
- Tumor markers of patients suggest the possibility of tumor.
- Patients with neuromuscular disease, inflammatory bowel disease, functional gastrointestinal disease;
- The patient has other connective tissue diseases or disorders.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Nonmyopathic dermatomyositis with interstitial lung disease
|
Classical dermatomyositis with interstitial lung disease
|
Rheumatic disease with interstitial lung disease in non-inflammatory myopathy
|
Healthy adult
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
T helper 1 cell
Time Frame: 2023-04-01 - 2024-06-30
|
Th1 cells are a type of lymphocytes that can produce pro-inflammatory cytokines to support the body's immune response.
|
2023-04-01 - 2024-06-30
|
T helper 2 cell
Time Frame: 2023-04-01 - 2024-06-30
|
Th2 is a T cell subset that can secrete Th2 type cytokines (such as interleukin IL-4, IL-5, IL-10 and IL-13, etc.), belonging to CD4+T cells.
|
2023-04-01 - 2024-06-30
|
T helper 17 cell
Time Frame: 2023-04-01 - 2024-06-30
|
Th17 cells are an important subset of CD4+T lymphocytes, which can express specific transcription factor RORγT and secrete cytokine IL-17.
|
2023-04-01 - 2024-06-30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2023
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
June 30, 2024
Study Registration Dates
First Submitted
November 13, 2023
First Submitted That Met QC Criteria
November 19, 2023
First Posted (Actual)
November 28, 2023
Study Record Updates
Last Update Posted (Actual)
November 28, 2023
Last Update Submitted That Met QC Criteria
November 19, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- YXH2022ZX03223
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatomyositis
-
Istituto Giannina GasliniPediatric Rheumatology International Trials OrganizationCompletedJuvenile DermatomyositisItaly
-
The First Hospital of Jilin UniversityCompletedJuvenile Dermatomyositis
-
The Cleveland ClinicMallinckrodtCompletedDermatomyositis | Juvenile DermatomyositisUnited States
-
Biotech Pharmaceutical Co., Ltd.Not yet recruitingDermatomyositis, Adult Type
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingDermatomyositis, Adult TypeChina
-
Tulane UniversityCompletedDermatomyositis, Adult TypeUnited States
-
Second Affiliated Hospital, School of Medicine,...RecruitingGastric Mucosal Manifestations in Patients With DermatomyositisChina
-
George Washington UniversityCompleted
-
Novartis PharmaceuticalsTerminatedActive DermatomyositisUnited States, Czechia, Japan
-
University Hospital, Strasbourg, FranceUnknown